Jennifer Odren, DO
Nephrology · Saint Clair Shores, MINPI 1821384249
Payments from drug & device makers
Across 288 payments — averaging $2154.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$172K
- Akebia Therapeutics Inc$125K
- Vertex$125K
- AstraZeneca$112K
- Novo Nordisk AS$24K
- GSK$24K
- plus $37K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 80 | $172,266 |
| Akebia Therapeutics Inc | 13 | $125,352 |
| Vertex | 5 | $125,070 |
| AstraZeneca | 31 | $112,427 |
| Novo Nordisk AS | 3 | $24,349 |
| GSK | 9 | $24,110 |
| Boehringer Ingelheim International GmbH | 5 | $23,135 |
| Genentech, Inc. | 2 | $10,806 |
| Amgen(2 entities) | 40 | $805 |
| Aurinia Pharma U.S., Inc. | 14 | $290 |
| Novartis | 14 | $282 |
| Mallinckrodt Hospital Products Inc. | 9 | $210 |
| Boehringer Ingelheim | 9 | $198 |
| Otsuka America Pharmaceutical, Inc. | 5 | $175 |
| Bayer | 9 | $157 |
| Vifor Pharma, Inc. | 8 | $154 |
| Novo Nordisk | 6 | $122 |
| Ardelyx, Inc. | 5 | $106 |
| Calliditas Therapeutics US Inc. | 5 | $103 |
| Apellis Pharmaceuticals, Inc. | 2 | $69 |
| Fresenius USA Marketing, Inc. | 3 | $54 |
| Mallinckrodt Enterprises LLC | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 2 | $33 |
| Travere Therapeutics, Inc. | 2 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
| Ascendis Pharma Endocrinology Inc | 1 | $14 |
How this compares
$620,419 in reported general payments places this provider in the 95th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Saint Clair Shores
- Richard CrossSaint Clair Shores$96K
- Faten AyyoubSaint Clair Shores$36K
- Blessing OkoronkwoSaint Clair Shores$12K
- Matthias KretzlerAnn Arbor$7.8M
- Fahd Al-SaghirPontiac$3.9M
- Kiran SaraiyaWarren$3.1M
- Alexander YevzlinAnn Arbor$1.3M
- Christopher ProvenzanoShelby Township$1.2M
- Joel TopfRoseville$1.1M
- Zeenat BhatAnn Arbor$592K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.